No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.
No article has been written about this topic yet.
Be the first one to add some text.
Loading AI-assisted edit mode...
Timeline
May 13, 2020
QurAlis officially launches under a $42 million series A round with a focus on new therapies for amyotrophic lateral sclerosis (ALS) and genetically related frontotemporal dementia (FTD).
November 19, 2018
QurAlis raises a $5,500,000 seed round from BioInnovation Capital.
November 2018
QurAlis raises a $5,500,000 seed round from Viva Biotech Limited, Amgen Ventures, MP Healthcare Venture Management and BioInnovation Capital.
Funding rounds
Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
QurAlis Raises $5.5 Million Seed Round
BusinessWire
Web
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
Ben Adams
July 1, 2020
FierceBiotech
In May, startup QurAlis got a $42 million series A toward targeting the genetic causes of two rare diseases: amyotrophic lateral sclerosis and genetically related frontotemporal dementia.
Ben Adams
May 13, 2020
FierceBiotech
QurAlis has officially launched under a $42 million series A round with a focus on new therapies for amyotrophic lateral sclerosis and genetically related frontotemporal dementia.
References
Is a
Company attributes
Industry
Location
Crunchbase
Investors
Total funding amount (USD)
11,000,000
Latest funding round date
November 19, 2018
